Ashish Kamat, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    Janssen (+Taris)
    Date added:
    Date updated:
    09/26/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Fergene
    Date added:
    Date updated:
    09/26/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Roche
    Date added:
    Date updated:
    09/26/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Engene
    Date added:
    Date updated:
    09/26/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Ferring
    Date added:
    Date updated:
    09/26/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    TMC Innovation
    Date added:
    Date updated:
    09/26/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Biological Dynamics
    Date added:
    Date updated:
    09/26/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Urogen
    Date added:
    Date updated:
    09/26/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Incyte DSMB
    Date added:
    Date updated:
    09/26/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Theralase
    Date added:
    Date updated:
    09/26/2025

Pages

Return to The Journal of Urology Vol. 210 (2023): November